241 related articles for article (PubMed ID: 19636019)
1. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
Efstathiou JA; Bae K; Shipley WU; Kaufman DS; Hagan MP; Heney NM; Sandler HM
J Clin Oncol; 2009 Sep; 27(25):4055-61. PubMed ID: 19636019
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
3. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
5. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.
Liu M; Pickles T; Agranovich A; Berthelet E; Duncan G; Keyes M; Kwan W; McKenzie M; Morris J; Pai H; Tyldesley S; Wu J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):59-67. PubMed ID: 14697421
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
7. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Mitin T; George A; Zietman AL; Heney NM; Kaufman DS; Uzzo RG; Dreicer R; Wallace HJ; Souhami L; Dobelbower MC; Sandler HM; Shipley WU
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):67-74. PubMed ID: 26700703
[TBL] [Abstract][Full Text] [Related]
9. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
10. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Coen JJ; Zhang P; Saylor PJ; Lee CT; Wu CL; Parker W; Lautenschlaeger T; Zietman AL; Efstathiou JA; Jani AB; Kucuk O; Souhami L; Rodgers JP; Sandler HM; Shipley WU
J Clin Oncol; 2019 Jan; 37(1):44-51. PubMed ID: 30433852
[TBL] [Abstract][Full Text] [Related]
11. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.
Audenet F; Waingankar N; Ferket BS; Niglio SA; Marqueen KE; Sfakianos JP; Galsky MD
J Urol; 2018 Nov; 200(5):996-1004. PubMed ID: 29879397
[TBL] [Abstract][Full Text] [Related]
14. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
15. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).
Michaelson MD; Hu C; Pham HT; Dahl DM; Lee-Wu C; Swanson GP; Vuky J; Lee RJ; Souhami L; Chang B; George A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):995-1001. PubMed ID: 28333021
[TBL] [Abstract][Full Text] [Related]
17. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
[TBL] [Abstract][Full Text] [Related]
19. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Chetner MP; Souhami L; Zlotecki RA; Sause WT; True LD
Oncologist; 2000; 5(6):471-6. PubMed ID: 11110598
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
